To include your compound in the COVID-19 Resource Center, submit it here.

Vivus reports topiramate data ahead of Qnexa resubmission

Vivus Inc. (NASDAQ:VVUS) said infants exposed to topiramate in utero did not have a significantly increased risk of developing oral clefts or major congenital malformations compared

Read the full 268 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE